$85.66
Axsome Therapeutics is a biotechnology business based in the US. Axsome Therapeutics shares (AXSM) are listed on the NASDAQ and all prices are listed in US Dollars. Axsome Therapeutics employs 569 staff and has a trailing 12-month revenue of around $251 million.
Our top picks for where to buy Axsome Therapeutics stock
How to buy Axsome Therapeutics stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – AXSM. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Axsome Therapeutics stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Axsome Therapeutics stock price (NASDAQ: AXSM)
Use our graph to track the performance of AXSM stocks over time.Axsome Therapeutics shares at a glance
Latest market close | $86.05 |
---|---|
52-week range | $55.02 - $98.40 |
50-day moving average | $77.60 |
200-day moving average | $75.91 |
Wall St. target price | $124.73 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-6.45 |
Is it a good time to buy Axsome Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Axsome Therapeutics price performance over time
Historical closes compared with the close of $86.05 from 2024-07-22
1 week (2024-07-17) | 2.76% |
---|---|
1 month (2024-06-24) | 9.62% |
3 months (2024-04-24) | 20.91% |
6 months (2024-01-24) | -6.24% |
1 year (2023-07-24) | 17.07% |
---|---|
2 years (2022-07-22) | 113.47% |
3 years (2021-07-23) | 60.30% |
5 years (2019-07-24) | 232.88% |
Axsome Therapeutics financials
Revenue TTM | $251 million |
---|---|
Gross profit TTM | $45.9 million |
Return on assets TTM | -32.76% |
Return on equity TTM | -231.68% |
Profit margin | -118.07% |
Book value | $3.04 |
Market Capitalization | $4.1 billion |
TTM: trailing 12 months
Axsome Therapeutics share dividends
We're not expecting Axsome Therapeutics to pay a dividend over the next 12 months.
Axsome Therapeutics share price volatility
Over the last 12 months, Axsome Therapeutics's shares have ranged in value from as little as $55.02 up to $98.4. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Axsome Therapeutics's is 1.254. This would suggest that Axsome Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Axsome Therapeutics overview
Axsome Therapeutics, Inc. , a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Frequently asked questions
nullWhat percentage of Axsome Therapeutics is owned by insiders or institutions?
Currently 17.041% of Axsome Therapeutics shares are held by insiders and 82.585% by institutions. How many people work for Axsome Therapeutics?
Latest data suggests 569 work at Axsome Therapeutics. When does the fiscal year end for Axsome Therapeutics?
Axsome Therapeutics's fiscal year ends in December. Where is Axsome Therapeutics based?
Axsome Therapeutics's address is: One World Trade Center, New York, NY, United States, 10007 What is Axsome Therapeutics's ISIN number?
Axsome Therapeutics's international securities identification number is: US05464T1043 What is Axsome Therapeutics's CUSIP number?
Axsome Therapeutics's Committee on Uniform Securities Identification Procedures number is: 05464T104
More guides on Finder
-
Opto review 2024: $0 commission, fractional theme investing
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
-
Best paper trading platforms to practice trading with fake money [2024]
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
-
Put options explained
Learn the basics of put options: what they are, how they work and a few examples.
-
Best broker cash sweep rates for July 2024
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
-
7 best day trading platforms of July 2024
These are the best day trading platforms, according to Finder’s comprehensive analysis.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
11 apps like Webull you need to consider
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
7 best ways to invest $10K
Check out our 7 ideas for how to invest $10K to maximize your money.
-
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
Ask a question